1. Class action notice for CRBU shareholders highlights misleading statements about CB-010. 2. Claims suggest overstatements on CB-010's safety and commercial potential. 3. Allegations include risks of insufficient funding for ongoing research activities. 4. Shareholders encouraged to register for potential lead plaintiff appointment.
The allegations point to significant operational and financial issues, harming investor confidence. Similar situations have historically resulted in substantial stock price declines.
Legal actions often impede stock performance and investor trust, especially with fundraising risks. The importance is heightened due to the specific allegations against CRBU.
Immediate legal challenges and investor concerns are likely to affect CRBU's stock quickly. Past cases show swift impacts post-announcement of class actions.
The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).
Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=125752&from=4
July 14, 2023 to July 16, 2024
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) they had overstated CB-010's safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010's overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (iii) all the foregoing was likely to have a significant negative impact on Caribou's business and operations; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.
February 24, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=125752&from=4
Once you register as a shareholder who purchased shares of CRBU during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 24, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE The Gross Law Firm